Status:
COMPLETED
Therapeutic Drug Monitoring - Targeting IMproved Effectiveness
Lead Sponsor:
Manchester University NHS Foundation Trust
Conditions:
Pneumonia
Sepsis
Eligibility:
All Genders
18+ years
Brief Summary
Severe infections can be caused by various organisms, such as bacteria or viruses, and lead to otherwise healthy people getting very unwell, sometimes needing treatment in hospital or even intensive c...
Eligibility Criteria
Inclusion
- Age \> 18 years;
- Admitted to intensive care;
- Treated for presumed or confirmed lower respiratory tract infection;
- Receiving OR about to receive the first dose of intravenous antimicrobials (either meropenem of piperacillin/tazobactam);
- Valid informed consent OR enrolment through deferred consent appropriate.
Exclusion
- Severe anaemia (haemoglobin level \< 70 g/L);
- Unlikely to survive 24 hours as judged by the treating physician;
- Study antimicrobial course started more than 24 hours ago.
Key Trial Info
Start Date :
December 12 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 21 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05971979
Start Date
December 12 2023
End Date
June 21 2024
Last Update
November 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wythenshawe Hospital, Manchester University NHS Foundation Trust
Manchester, United Kingdom, M23 9LT